Drug may prevent some migraine attacks in children and teens

, /PRNewswire/ -- For children and teens living with migraine, there may be a new preventive treatment, according to a preliminary study released February 26, 2025, that will be presented at the American Academy of Neurology's 77^th Annual Meeting taking place April 5–9, 2025, in San Diego and online. Researchers found the drug zonisamide, which has been used to treat seizures, may reduce migraine days in this age group. This study does not prove that zonisamide reduces migraine days; it only shows an association.

"Migraine disease is debilitating and can lead to kids having to miss school and other activities," said author Anisa Kelley, MD, of Northwestern University Feinberg School of Medicine in Chicago. "Currently, there is only one FDA-approved migraine preventative medication for this age group. Our results are encouraging, showing zonisamide may be another option for reducing migraine attacks."

For the study, researchers reviewed health records at one institution. They identified 256 children and teens who had been diagnosed with migraine and prescribed preventative zonisamide. Of these participants, 28% had difficult-to-treat migraine, which was defined as having migraine disease unsuccessfully treated with two or more previous medications. Researchers documented the number of headache days per month for each participant both before and after starting zonisamide.

They then divided participants into three subgroups based on how long they took the medication before a follow-up visit with a physician. The first group followed up in the first month, the second group within two to six months and the third group, after six months.

For all participants, the median number of headache days per month reduced from 18 to six at the first follow-up visit. When comparing between the groups, the subgroup that followed up within two to six months had the largest reduction with a median decrease of six headache days per month. Kelley noted that the data suggested the drug was most effective after at least two months of use.

The data also suggested that the drug was effective for both those with difficult-to-treat migraine disease and those without.

"It's very exciting that we may have an effective way to treat difficult migraine disease in children and teens, however it's important to note that our study did have limitations," said Kelley. "For instance, our study did not compare people taking the medication to people who did not take the medication. Future studies are needed with control groups to confirm our results."

This study was funded by Stanley Manne Children's Research Institute at Ann & Robert H. Lurie Children's Hospital of Chicago.

Discover more about migraine at BrainandLife.org, from the American Academy of Neurology. This resource also offers a magazine, podcast, and books that connect patients, caregivers and anyone interested in brain health with the most trusted information, straight from the world's leading experts in brain health. Follow Brain & Life® on Facebook, X, and Instagram.

The American Academy of Neurology is the leading voice in brain health. As the world's largest association of neurologists and neuroscience professionals with more than 40,000 members, the AAN provides access to the latest news, science and research affecting neurology for patients, caregivers, physicians and professionals alike. The AAN's mission is to enhance member career fulfillment and promote brain health for all. A neurologist is a doctor who specializes in the diagnosis, care and treatment of brain, spinal cord and nervous system diseases such as Alzheimer's disease, stroke, concussion, epilepsy, Parkinson's disease, multiple sclerosis, headache and migraine.

Explore the latest in neurological disease and brain health, from the minds at the AAN at AAN.com or find us on Facebook, X, Instagram, LinkedIn, and YouTube.

When posting to social media channels about this research, we encourage you to use the American Academy of Neurology's Annual Meeting hashtag #AANAM. 

SOURCE American Academy of Neurology